The global PD-1 antibody drug market is experiencing unprecedented growth, as these drugs have revolutionized cancer treatment by targeting immune checkpoints.
The global PD-1 antibody drug market is experiencing unprecedented growth, revolutionizing the field of cancer treatment. PD-1 (Programmed Death-1) is a protein that helps regulate the immune system, and cancer cells often exploit this pathway to evade immune attack. PD-1 inhibitors are a class of immunotherapy drugs designed to block the PD-1 pathway, unleashing the immune system to recognize and destroy cancer cells. These drugs have demonstrated remarkable clinical success in treating various cancers, including melanoma, lung cancer, and kidney cancer, offering durable responses and improved survival rates in many patients. The increasing prevalence of cancer worldwide, coupled with the growing understanding of the immune system's role in cancer, is driving significant demand for PD-1 inhibitors. Furthermore, ongoing research and development efforts are expanding the therapeutic potential of these drugs, with ongoing clinical trials exploring their use in combination with other therapies and in the treatment of a wider range of cancers. The global PD-1 antibody drug market is poised for continued growth, driven by ongoing innovation, expanding clinical applications, and the increasing availability of these life-saving therapies.
The global PD-1 Antibody Drug market size is projected to grow from US$ 32280 million in 2023 to US$ 85010 million in 2030; it is expected to grow at a CAGR of 14.8% from 2024 to 2030. PD-1 is an immune checkpoint inhibitor, which is relatively widely used clinically. Publisher' newest research report, the “PD-1 Antibody Drug Industry Forecast” looks at past sales and reviews total world PD-1 Antibody Drug sales in 2023, providing a comprehensive analysis by region and market sector of projected PD-1 Antibody Drug sales for 2024 through 2030. With PD-1 Antibody Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PD-1 Antibody Drug industry. This Insight Report provides a comprehensive analysis of the global PD-1 Antibody Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PD-1 Antibody Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global PD-1 Antibody Drug market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PD-1 Antibody Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PD-1 Antibody Drug.
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Within the PD-1 antibody drug market, two primary types of inhibitors dominate: PD-1 inhibitors and PD-L1 inhibitors. PD-1 inhibitors directly target the PD-1 receptor on immune cells, while PD-L1 inhibitors target the PD-L1 ligand expressed on cancer cells. Both classes of inhibitors work by blocking the interaction between PD-1 and PD-L1, thereby releasing the brakes on the immune system and enabling it to effectively recognize and attack cancer cells. PD-1 inhibitors have demonstrated significant clinical success in a wide range of cancers, including melanoma, lung cancer, and kidney cancer. Key examples of PD-1 inhibitors include nivolumab (Opdivo), pembrolizumab (Keytruda), and cemiplimab (Libtayo). PD-L1 inhibitors, such as atezolizumab (Tecentriq), durvalumab (Imfinzi), and avelumab (Bavencio), have also shown promising results in various cancers. The choice between PD-1 and PD-L1 inhibitors often depends on factors such as the specific type of cancer, the patient's individual characteristics, and the availability of treatment options. The continuous development of new PD-1 and PD-L1 inhibitors, as well as ongoing research into combination therapies, is driving significant innovation within this market segment. These advancements are expected to further expand the therapeutic potential of these drugs and improve outcomes for patients with cancer.
The global PD-1 antibody drug market finds significant application across a diverse range of cancer types, reflecting the versatility of these immunotherapies. Lung cancer, including non-small cell lung cancer (NSCLC), constitutes a major application area, with PD-1 inhibitors demonstrating substantial clinical benefits in both early and advanced stages of the disease. Melanoma, a type of skin cancer, represents a landmark success story for PD-1 inhibitors, demonstrating remarkable efficacy and establishing these drugs as a cornerstone of melanoma treatment. Beyond these, PD-1 inhibitors have shown significant promise in treating various other cancers, including renal cell carcinoma (kidney cancer), head and neck cancer, bladder cancer, and Hodgkin lymphoma. The applications of PD-1 inhibitors are continually expanding through ongoing research and clinical trials. These investigations are exploring the efficacy of these drugs in a wider range of cancers, such as gastric cancer, colorectal cancer, cervical cancer, and various types of head and neck cancers. Furthermore, research is focused on identifying predictive biomarkers to identify patients most likely to benefit from PD-1 inhibitor therapy, optimizing treatment strategies, and exploring combination therapies with other immunotherapies, chemotherapies, and targeted therapies. The expanding range of applications for PD-1 inhibitors is revolutionizing cancer treatment by offering new hope to patients with previously difficult-to-treat cancers and driving the development of more personalized and effective cancer therapies.
The global PD-1 antibody drug market exhibits significant regional variations driven by a complex interplay of factors, including healthcare infrastructure development, technological advancements, regulatory frameworks, disease prevalence, and economic conditions. North America currently dominates the market, driven by robust research and development activities, early adoption of advanced technologies, well-established healthcare infrastructure, and a strong focus on personalized medicine. Europe, with its advanced healthcare systems, emphasis on preventative healthcare, and stringent regulatory frameworks, also holds a significant market share. The Asia-Pacific region is witnessing rapid growth, fueled by increasing healthcare expenditure, rising prevalence of cancers, and growing awareness of immunotherapy. However, the market landscape within this region is diverse, with varying levels of technological adoption and healthcare infrastructure development across different countries. Latin America is projected to experience substantial growth, driven by increasing investments in healthcare infrastructure, rising prevalence of cancers, and growing demand for advanced diagnostic and therapeutic solutions. The Middle East and Africa region presents a diverse market with significant untapped potential, characterized by varying levels of healthcare development, significant reliance on traditional therapies, and challenges such as limited healthcare infrastructure and resource constraints. Overall, the global PD-1 antibody drug market is poised for significant growth, driven by technological advancements, increasing healthcare expenditure, and the growing demand for personalized and precision medicine, although regional variations will continue to influence market dynamics.
Make this report your own
Have queries/questions regarding a report
Take advantage of intelligence tailored to your business objective
Sikandar Kesari
Research Analyst
Don't pay for what you don't need. Save 30%
Customise your report by selecting specific countries or regions
13.15.2 3SBio PD-1 Antibody Drug Product Portfolios and Specifications
13.15.3 3SBio PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 3SBio Main Business Overview
13.15.5 3SBio Latest Developments
14 Research Findings and Conclusion
Table 1. PD-1 Antibody Drug Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. PD-1 Antibody Drug Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Pembrolizumab
Table 4. Major Players of Nivolumab
Table 5. Major Players of Sindilimab
Table 6. Major Players of Toripalimab
Table 7. Major Players of Other
Table 8. Global PD-1 Antibody Drug Sales by Type (2019-2024) & (K Units)
Table 9. Global PD-1 Antibody Drug Sales Market Share by Type (2019-2024)
Table 10. Global PD-1 Antibody Drug Revenue by Type (2019-2024) & ($ million)
Table 11. Global PD-1 Antibody Drug Revenue Market Share by Type (2019-2024)
Table 12. Global PD-1 Antibody Drug Sale Price by Type (2019-2024) & (US$/Unit)
Table 13. Global PD-1 Antibody Drug Sales by Application (2019-2024) & (K Units)
Table 14. Global PD-1 Antibody Drug Sales Market Share by Application (2019-2024)
Table 15. Global PD-1 Antibody Drug Revenue by Application (2019-2024)
Table 16. Global PD-1 Antibody Drug Revenue Market Share by Application (2019-2024)
Table 17. Global PD-1 Antibody Drug Sale Price by Application (2019-2024) & (US$/Unit)
Table 18. Global PD-1 Antibody Drug Sales by Company (2019-2024) & (K Units)
Table 19. Global PD-1 Antibody Drug Sales Market Share by Company (2019-2024)
Table 20. Global PD-1 Antibody Drug Revenue by Company (2019-2024) ($ Millions)
Table 21. Global PD-1 Antibody Drug Revenue Market Share by Company (2019-2024)
Table 22. Global PD-1 Antibody Drug Sale Price by Company (2019-2024) & (US$/Unit)
Table 23. Key Manufacturers PD-1 Antibody Drug Producing Area Distribution and Sales Area
Table 24. Players PD-1 Antibody Drug Products Offered
Table 25. PD-1 Antibody Drug Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global PD-1 Antibody Drug Sales by Geographic Region (2019-2024) & (K Units)
Table 29. Global PD-1 Antibody Drug Sales Market Share Geographic Region (2019-2024)
Table 30. Global PD-1 Antibody Drug Revenue by Geographic Region (2019-2024) & ($ millions)
Table 31. Global PD-1 Antibody Drug Revenue Market Share by Geographic Region (2019-2024)
Table 32. Global PD-1 Antibody Drug Sales by Country/Region (2019-2024) & (K Units)
Table 33. Global PD-1 Antibody Drug Sales Market Share by Country/Region (2019-2024)
Table 34. Global PD-1 Antibody Drug Revenue by Country/Region (2019-2024) & ($ millions)
Table 35. Global PD-1 Antibody Drug Revenue Market Share by Country/Region (2019-2024)
Table 36. Americas PD-1 Antibody Drug Sales by Country (2019-2024) & (K Units)
Table 37. Americas PD-1 Antibody Drug Sales Market Share by Country (2019-2024)
Table 38. Americas PD-1 Antibody Drug Revenue by Country (2019-2024) & ($ Millions)
Table 39. Americas PD-1 Antibody Drug Revenue Market Share by Country (2019-2024)
Table 40. Americas PD-1 Antibody Drug Sales by Type (2019-2024) & (K Units)
Table 41. Americas PD-1 Antibody Drug Sales by Application (2019-2024) & (K Units)
Table 42. APAC PD-1 Antibody Drug Sales by Region (2019-2024) & (K Units)
Table 43. APAC PD-1 Antibody Drug Sales Market Share by Region (2019-2024)
Table 44. APAC PD-1 Antibody Drug Revenue by Region (2019-2024) & ($ Millions)
Table 45. APAC PD-1 Antibody Drug Revenue Market Share by Region (2019-2024)
Table 46. APAC PD-1 Antibody Drug Sales by Type (2019-2024) & (K Units)
Table 47. APAC PD-1 Antibody Drug Sales by Application (2019-2024) & (K Units)
Table 48. Europe PD-1 Antibody Drug Sales by Country (2019-2024) & (K Units)
Table 49. Europe PD-1 Antibody Drug Sales Market Share by Country (2019-2024)
Table 50. Europe PD-1 Antibody Drug Revenue by Country (2019-2024) & ($ Millions)
Table 51. Europe PD-1 Antibody Drug Revenue Market Share by Country (2019-2024)
Table 52. Europe PD-1 Antibody Drug Sales by Type (2019-2024) & (K Units)
Table 53. Europe PD-1 Antibody Drug Sales by Application (2019-2024) & (K Units)
Table 54. Middle East & Africa PD-1 Antibody Drug Sales by Country (2019-2024) & (K Units)
Table 55. Middle East & Africa PD-1 Antibody Drug Sales Market Share by Country (2019-2024)
Table 56. Middle East & Africa PD-1 Antibody Drug Revenue by Country (2019-2024) & ($ Millions)
Table 57. Middle East & Africa PD-1 Antibody Drug Revenue Market Share by Country (2019-2024)
Table 58. Middle East & Africa PD-1 Antibody Drug Sales by Type (2019-2024) & (K Units)
Table 59. Middle East & Africa PD-1 Antibody Drug Sales by Application (2019-2024) & (K Units)
Table 60. Key Market Drivers & Growth Opportunities of PD-1 Antibody Drug
Table 61. Key Market Challenges & Risks of PD-1 Antibody Drug
Table 62. Key Industry Trends of PD-1 Antibody Drug
Table 63. PD-1 Antibody Drug Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. PD-1 Antibody Drug Distributors List
Table 66. PD-1 Antibody Drug Customer List
Table 67. Global PD-1 Antibody Drug Sales Forecast by Region (2025-2030) & (K Units)
Table 68. Global PD-1 Antibody Drug Revenue Forecast by Region (2025-2030) & ($ millions)
Table 69. Americas PD-1 Antibody Drug Sales Forecast by Country (2025-2030) & (K Units)
Table 70. Americas PD-1 Antibody Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 71. APAC PD-1 Antibody Drug Sales Forecast by Region (2025-2030) & (K Units)
Table 72. APAC PD-1 Antibody Drug Revenue Forecast by Region (2025-2030) & ($ millions)
Table 73. Europe PD-1 Antibody Drug Sales Forecast by Country (2025-2030) & (K Units)
Table 74. Europe PD-1 Antibody Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 75. Middle East & Africa PD-1 Antibody Drug Sales Forecast by Country (2025-2030) & (K Units)
Table 76. Middle East & Africa PD-1 Antibody Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 77. Global PD-1 Antibody Drug Sales Forecast by Type (2025-2030) & (K Units)
Table 78. Global PD-1 Antibody Drug Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 79. Global PD-1 Antibody Drug Sales Forecast by Application (2025-2030) & (K Units)
Table 80. Global PD-1 Antibody Drug Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 81. Novartis Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 82. Novartis PD-1 Antibody Drug Product Portfolios and Specifications
Table 83. Novartis PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 84. Novartis Main Business
Table 85. Novartis Latest Developments
Table 86. Thermo Fisher Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 87. Thermo Fisher PD-1 Antibody Drug Product Portfolios and Specifications
Table 88. Thermo Fisher PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 89. Thermo Fisher Main Business
Table 90. Thermo Fisher Latest Developments
Table 91. InvivoGen Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 92. InvivoGen PD-1 Antibody Drug Product Portfolios and Specifications
Table 93. InvivoGen PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 94. InvivoGen Main Business
Table 95. InvivoGen Latest Developments
Table 96. BioVision Inc. Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 97. BioVision Inc. PD-1 Antibody Drug Product Portfolios and Specifications
Table 98. BioVision Inc. PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 99. BioVision Inc. Main Business
Table 100. BioVision Inc. Latest Developments
Table 101. Abcam Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 102. Abcam PD-1 Antibody Drug Product Portfolios and Specifications
Table 103. Abcam PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 104. Abcam Main Business
Table 105. Abcam Latest Developments
Table 106. Bristol-Myers Squibb Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 107. Bristol-Myers Squibb PD-1 Antibody Drug Product Portfolios and Specifications
Table 108. Bristol-Myers Squibb PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 109. Bristol-Myers Squibb Main Business
Table 110. Bristol-Myers Squibb Latest Developments
Table 111. Merck Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 112. Merck PD-1 Antibody Drug Product Portfolios and Specifications
Table 113. Merck PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 114. Merck Main Business
Table 115. Merck Latest Developments
Table 116. Ono Pharmaceutical Co., Ltd Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 117. Ono Pharmaceutical Co., Ltd PD-1 Antibody Drug Product Portfolios and Specifications
Table 118. Ono Pharmaceutical Co., Ltd PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 119. Ono Pharmaceutical Co., Ltd Main Business
Table 120. Ono Pharmaceutical Co., Ltd Latest Developments
Table 121. Eli Lilly Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 122. Eli Lilly PD-1 Antibody Drug Product Portfolios and Specifications
Table 123. Eli Lilly PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 124. Eli Lilly Main Business
Table 125. Eli Lilly Latest Developments
Table 126. Chugai Pharmaceutical Co., Ltd Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 127. Chugai Pharmaceutical Co., Ltd PD-1 Antibody Drug Product Portfolios and Specifications
Table 128. Chugai Pharmaceutical Co., Ltd PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 129. Chugai Pharmaceutical Co., Ltd Main Business
Table 130. Chugai Pharmaceutical Co., Ltd Latest Developments
Table 131. BeiGene Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 132. BeiGene PD-1 Antibody Drug Product Portfolios and Specifications
Table 133. BeiGene PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 134. BeiGene Main Business
Table 135. BeiGene Latest Developments
Table 136. AbbVie Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 137. AbbVie PD-1 Antibody Drug Product Portfolios and Specifications
Table 138. AbbVie PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 139. AbbVie Main Business
Table 140. AbbVie Latest Developments
Table 141. TG Therapeutics, Inc Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 142. TG Therapeutics, Inc PD-1 Antibody Drug Product Portfolios and Specifications
Table 143. TG Therapeutics, Inc PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 144. TG Therapeutics, Inc Main Business
Table 145. TG Therapeutics, Inc Latest Developments
Table 146. Beijing Yiqiao Shenzhou Technology Co., Ltd. Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 147. Beijing Yiqiao Shenzhou Technology Co., Ltd. PD-1 Antibody Drug Product Portfolios and Specifications
Table 148. Beijing Yiqiao Shenzhou Technology Co., Ltd. PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 149. Beijing Yiqiao Shenzhou Technology Co., Ltd. Main Business
Table 150. Beijing Yiqiao Shenzhou Technology Co., Ltd. Latest Developments
Table 151. 3SBio Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 152. 3SBio PD-1 Antibody Drug Product Portfolios and Specifications
Table 153. 3SBio PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 154. 3SBio Main Business
Table 155. 3SBio Latest Developments
List of
Figure 1. Picture of PD-1 Antibody Drug
Figure 2. PD-1 Antibody Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global PD-1 Antibody Drug Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global PD-1 Antibody Drug Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. PD-1 Antibody Drug Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Pembrolizumab
Figure 10. Product Picture of Nivolumab
Figure 11. Product Picture of Sindilimab
Figure 12. Product Picture of Toripalimab
Figure 13. Product Picture of Other
Figure 14. Global PD-1 Antibody Drug Sales Market Share by Type in 2023
Figure 15. Global PD-1 Antibody Drug Revenue Market Share by Type (2019-2024)
Figure 16. PD-1 Antibody Drug Consumed in Hospital
Figure 17. Global PD-1 Antibody Drug Market: Hospital (2019-2024) & (K Units)
Figure 18. PD-1 Antibody Drug Consumed in Clinic
Figure 19. Global PD-1 Antibody Drug Market: Clinic (2019-2024) & (K Units)
Figure 20. PD-1 Antibody Drug Consumed in Other
Figure 21. Global PD-1 Antibody Drug Market: Other (2019-2024) & (K Units)
Figure 22. Global PD-1 Antibody Drug Sales Market Share by Application (2023)
Figure 23. Global PD-1 Antibody Drug Revenue Market Share by Application in 2023
Figure 24. PD-1 Antibody Drug Sales Market by Company in 2023 (K Units)
Figure 25. Global PD-1 Antibody Drug Sales Market Share by Company in 2023
Figure 26. PD-1 Antibody Drug Revenue Market by Company in 2023 ($ Million)
Figure 27. Global PD-1 Antibody Drug Revenue Market Share by Company in 2023
Figure 28. Global PD-1 Antibody Drug Sales Market Share by Geographic Region (2019-2024)
Figure 29. Global PD-1 Antibody Drug Revenue Market Share by Geographic Region in 2023
Figure 30. Americas PD-1 Antibody Drug Sales 2019-2024 (K Units)
Figure 31. Americas PD-1 Antibody Drug Revenue 2019-2024 ($ Millions)
Figure 32. APAC PD-1 Antibody Drug Sales 2019-2024 (K Units)
Figure 33. APAC PD-1 Antibody Drug Revenue 2019-2024 ($ Millions)
Figure 34. Europe PD-1 Antibody Drug Sales 2019-2024 (K Units)
Figure 35. Europe PD-1 Antibody Drug Revenue 2019-2024 ($ Millions)
Figure 36. Middle East & Africa PD-1 Antibody Drug Sales 2019-2024 (K Units)
Figure 37. Middle East & Africa PD-1 Antibody Drug Revenue 2019-2024 ($ Millions)
Figure 38. Americas PD-1 Antibody Drug Sales Market Share by Country in 2023
Figure 39. Americas PD-1 Antibody Drug Revenue Market Share by Country in 2023
Figure 40. Americas PD-1 Antibody Drug Sales Market Share by Type (2019-2024)
Figure 41. Americas PD-1 Antibody Drug Sales Market Share by Application (2019-2024)
Figure 42. United States PD-1 Antibody Drug Revenue Growth 2019-2024 ($ Millions)
Figure 43. Canada PD-1 Antibody Drug Revenue Growth 2019-2024 ($ Millions)
Figure 44. Mexico PD-1 Antibody Drug Revenue Growth 2019-2024 ($ Millions)
Figure 45. Brazil PD-1 Antibody Drug Revenue Growth 2019-2024 ($ Millions)
Figure 46. APAC PD-1 Antibody Drug Sales Market Share by Region in 2023
Figure 47. APAC PD-1 Antibody Drug Revenue Market Share by Regions in 2023
Figure 48. APAC PD-1 Antibody Drug Sales Market Share by Type (2019-2024)
Figure 49. APAC PD-1 Antibody Drug Sales Market Share by Application (2019-2024)
Figure 50. China PD-1 Antibody Drug Revenue Growth 2019-2024 ($ Millions)
Figure 51. Japan PD-1 Antibody Drug Revenue Growth 2019-2024 ($ Millions)
Figure 52. South Korea PD-1 Antibody Drug Revenue Growth 2019-2024 ($ Millions)
Figure 53. Southeast Asia PD-1 Antibody Drug Revenue Growth 2019-2024 ($ Millions)
Figure 54. India PD-1 Antibody Drug Revenue Growth 2019-2024 ($ Millions)
Figure 55. Australia PD-1 Antibody Drug Revenue Growth 2019-2024 ($ Millions)
Figure 56. China Taiwan PD-1 Antibody Drug Revenue Growth 2019-2024 ($ Millions)
Figure 57. Europe PD-1 Antibody Drug Sales Market Share by Country in 2023
Figure 58. Europe PD-1 Antibody Drug Revenue Market Share by Country in 2023
Figure 59. Europe PD-1 Antibody Drug Sales Market Share by Type (2019-2024)
Figure 60. Europe PD-1 Antibody Drug Sales Market Share by Application (2019-2024)
Figure 61. Germany PD-1 Antibody Drug Revenue Growth 2019-2024 ($ Millions)
Figure 62. France PD-1 Antibody Drug Revenue Growth 2019-2024 ($ Millions)
Figure 63. UK PD-1 Antibody Drug Revenue Growth 2019-2024 ($ Millions)
Figure 64. Italy PD-1 Antibody Drug Revenue Growth 2019-2024 ($ Millions)
Figure 65. Russia PD-1 Antibody Drug Revenue Growth 2019-2024 ($ Millions)
Figure 66. Middle East & Africa PD-1 Antibody Drug Sales Market Share by Country in 2023
Figure 67. Middle East & Africa PD-1 Antibody Drug Revenue Market Share by Country in 2023
Figure 68. Middle East & Africa PD-1 Antibody Drug Sales Market Share by Type (2019-2024)
Figure 69. Middle East & Africa PD-1 Antibody Drug Sales Market Share by Application (2019-2024)
Figure 70. Egypt PD-1 Antibody Drug Revenue Growth 2019-2024 ($ Millions)
Figure 71. South Africa PD-1 Antibody Drug Revenue Growth 2019-2024 ($ Millions)
Figure 72. Israel PD-1 Antibody Drug Revenue Growth 2019-2024 ($ Millions)
Figure 73. Turkey PD-1 Antibody Drug Revenue Growth 2019-2024 ($ Millions)
Figure 74. GCC Country PD-1 Antibody Drug Revenue Growth 2019-2024 ($ Millions)
Figure 75. Manufacturing Cost Structure Analysis of PD-1 Antibody Drug in 2023
Figure 76. Manufacturing Process Analysis of PD-1 Antibody Drug
Figure 77. Industry Chain Structure of PD-1 Antibody Drug
Figure 78. Channels of Distribution
Figure 79. Global PD-1 Antibody Drug Sales Market Forecast by Region (2025-2030)
Figure 80. Global PD-1 Antibody Drug Revenue Market Share Forecast by Region (2025-2030)
Figure 81. Global PD-1 Antibody Drug Sales Market Share Forecast by Type (2025-2030)
Figure 82. Global PD-1 Antibody Drug Revenue Market Share Forecast by Type (2025-2030)
Figure 83. Global PD-1 Antibody Drug Sales Market Share Forecast by Application (2025-2030)
Figure 84. Global PD-1 Antibody Drug Revenue Market Share Forecast by Application (2025-2030)
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information